Cargando…

The number of brain metastases predicts the survival of non‐small cell lung cancer patients with EGFR mutation status

BACKGROUND: Lung cancer is the common cause of cancer‐related deaths throughout the world, and brain is a frequent metastatic site of lung cancer. AIM: This research sought to evaluate the impact of the number of brain metastases in prognosticating non‐small cell lung cancer (NSCLC) patients account...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Jun, Li, Jingwei, Song, Lujia, He, Qiuyao, Wu, Yuxuan, Li, Linhui, Liu, Dan, Wang, Chengdi, Li, Weimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458511/ https://www.ncbi.nlm.nih.gov/pubmed/34766737 http://dx.doi.org/10.1002/cnr2.1550

Ejemplares similares

A comprehensive algorithm to distinguish between MPLC and IPM in multiple lung tumors patients
por: Shao, Jun, et al.
Publicado: (2020)

Deep Learning to Predict EGFR Mutation and PD-L1 Expression Status in Non-Small-Cell Lung Cancer on Computed Tomography Images
por: Wang, Chengdi, et al.
Publicado: (2021)

Clinicopathological variables influencing overall survival, recurrence and post-recurrence survival in resected stage I non-small-cell lung cancer
por: Wang, Chengdi, et al.
Publicado: (2020)

Persistent increase and improved survival of stage I lung cancer based on a large-scale real-world sample of 26,226 cases
por: Wang, Chengdi, et al.
Publicado: (2023)

Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival
por: Stanic, Karmen, et al.
Publicado: (2014)

The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases
por: Fujita, Yuya, et al.
Publicado: (2020)

Radiomic Signatures for Predicting EGFR Mutation Status in Lung Cancer Brain Metastases
por: Zheng, Lie, et al.
Publicado: (2022)

Predicting EGFR and PD-L1 Status in NSCLC Patients Using Multitask AI System Based on CT Images
por: Wang, Chengdi, et al.
Publicado: (2022)

The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
por: Wang, Chengdi, et al.
Publicado: (2021)

Distinct clinicopathologic factors and prognosis based on the presence of ground-glass opacity components in patients with resected stage I non-small cell lung cancer
por: Wang, Chengdi, et al.
Publicado: (2020)

Radiogenomic System for Non-Invasive Identification of Multiple Actionable Mutations and PD-L1 Expression in Non-Small Cell Lung Cancer Based on CT Images
por: Shao, Jun, et al.
Publicado: (2022)

The epidemiology and therapeutic options for the COVID-19
por: Li, Jingwei, et al.
Publicado: (2020)

A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations
por: Deng, Hui, et al.
Publicado: (2022)

Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs
por: Gui, Qi, et al.
Publicado: (2017)

Deep learning for predicting subtype classification and survival of lung adenocarcinoma on computed tomography
por: Wang, Chengdi, et al.
Publicado: (2021)

Emerging Role of Noncoding RNAs in EGFR TKI-Resistant Lung Cancer
por: Li, Jingwei, et al.
Publicado: (2022)

Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status
por: Zhang, Milan, et al.
Publicado: (2021)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
por: Shi, Liang, et al.
Publicado: (2021)

Effect of Different Timing of Local Brain Radiotherapy on Survival of EGFR-Mutated NSCLC Patients with Limited Brain Metastases
por: Wang, Yu, et al.
Publicado: (2023)

Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA
por: Zhang, Rui, et al.
Publicado: (2018)

The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
por: Bai, Hao, et al.
Publicado: (2017)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
por: Zhang, Jinyao, et al.
Publicado: (2021)

Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer
por: Bhandari, Shruti, et al.
Publicado: (2021)

The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing
por: Wang, Chengdi, et al.
Publicado: (2022)

Long-term survival of a non-small cell lung cancer patient with EGFR-mutated brain metastases: a case report
por: Wan, Yuming, et al.
Publicado: (2022)

Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients
por: Fan, Yun, et al.
Publicado: (2013)

Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC
por: Wang, Chengdi, et al.
Publicado: (2022)

Retracted: Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis
por: Qiu, Rong, et al.
Publicado: (2021)

EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer
por: Tomasini, Pascale, et al.
Publicado: (2016)

EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases
por: Lee, Hsin-Lun, et al.
Publicado: (2012)

First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Tatineni, Vineeth, et al.
Publicado: (2023)

The application of artificial intelligence and radiomics in lung cancer
por: Zhou, Yaojie, et al.
Publicado: (2020)

Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations
por: Ma, Chunhua, et al.
Publicado: (2020)

Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases
por: Goldstein, Iris M, et al.
Publicado: (2020)

EGFR-Driven Mutation in Non-Small-Cell Lung Cancer (NSCLC) Influences the Features and Outcome of Brain Metastases
por: Armocida, Daniele, et al.
Publicado: (2023)

Common nutritional/inflammatory indicators are not effective tools in predicting the overall survival of patients with small cell lung cancer undergoing first-line chemotherapy
por: Tian, Huohuan, et al.
Publicado: (2023)

Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer
por: Wang, Chengdi, et al.
Publicado: (2019)

Artificial intelligence-assisted decision making for prognosis and drug efficacy prediction in lung cancer patients: a narrative review
por: Li, Jingwei, et al.
Publicado: (2021)

The Application of Artificial Intelligence in the Diagnosis and Drug Resistance Prediction of Pulmonary Tuberculosis
por: Liang, Shufan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1rdmehuv86bhap0a9shfse1jlv